EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pulike Biological Engineering EBITDA Margin % Related Terms
Pulike Biological Engineering EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603566 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Pulike Biological Engineering's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulike Biological Engineering EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pulike Biological Engineering's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulike Biological Engineering (SHSE:603566) has a EBITDA Margin % of 18.15% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pulike Biological Engineering and its competitors. This is 35% below median its historical median of 27.72. Over the past decade, Pulike Biological Engineering's EBITDA Margin % has ranged from 17.95 to 33.88. According to the industry distribution chart, Pulike Biological Engineering ranks #178 out of 936 companies in the Biotechnology industry, placing it in the top 19%.
Is Pulike Biological Engineering's EBITDA Margin % too high?
Pulike Biological Engineering's current EBITDA Margin % of 18.15% is 35% below median its 10-year median of 27.72. Over the past 10 years, this metric has ranged from a low of 17.95 to a high of 33.88. Based on the distribution chart, Pulike Biological Engineering ranks #178 out of 936 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pulike Biological Engineering has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pulike Biological Engineering's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pulike Biological Engineering ranks #178 out of 936 companies for EBITDA Margin %. This places Pulike Biological Engineering in the top 19% of its industry — outperforming the majority of peers. Historically, Pulike Biological Engineering's own EBITDA Margin % has ranged from 17.95 to 33.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pulike Biological Engineering and its competitors. Pulike Biological Engineering's current EBITDA Margin % is 18.15%, which is 35% below median its own 10-year median of 27.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulike Biological Engineering stock overvalued right now?
Based on GuruFocus' analysis, Pulike Biological Engineering (SHSE:603566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.18, compared to a current price of ¥10.24 — trading 27.8% below its estimated fair value. The current EBITDA Margin % is 18.15%, which is 35% below median its 10-year median of 27.72. Pulike Biological Engineering's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pulike Biological Engineering (SHSE:603566), the current EBITDA Margin % is 18.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulike Biological Engineering (SHSE:603566) Overvalued in 2026?
Based on GuruFocus' analysis, Pulike Biological Engineering stock appears to be undervalued.
The current stock price of ¥10.24 is trading 27.8% below its estimated GF Value™ of ¥14.18.
GuruFocus considers Pulike Biological Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:603566:
EBITDA Margin %: 18.15% (35% below median its 10-year median of 27.72)
GF Value™: ¥14.18 vs. price of ¥10.24 (27.8% below fair value)
No single metric tells the full story. See the SHSE:603566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulike Biological Engineering Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603566 has been successfully added to your 
